Jack Meehan
Stock Analyst at Barclays
(3.08)
# 1,120
Out of 5,182 analysts
137
Total ratings
69.51%
Success rate
21.33%
Average return
Main Sectors:
Stocks Rated by Jack Meehan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LH Labcorp Holdings | Maintains: Equal-Weight | $275 → $290 | $273.72 | +5.95% | 17 | Oct 2, 2025 | |
| A Agilent Technologies | Maintains: Underweight | $120 → $125 | $115.48 | +8.24% | 20 | Feb 28, 2024 | |
| WAT Waters | Maintains: Equal-Weight | $275 → $288 | $304.24 | -5.34% | 10 | Aug 3, 2023 | |
| AVTR Avantor | Initiates: Overweight | $33 | $7.90 | +317.72% | 3 | Mar 3, 2021 | |
| ILMN Illumina | Initiates: Underweight | $325 | $127.38 | +155.14% | 8 | Mar 3, 2021 | |
| INMD InMode | Maintains: Overweight | $18 → $19 | $13.79 | +37.78% | 3 | Aug 17, 2020 | |
| DGX Quest Diagnostics | Maintains: Equal-Weight | $93 → $99 | $198.02 | -50.01% | 7 | Apr 23, 2020 | |
| ICLR ICON Public Limited Company | Maintains: Overweight | $170 → $180 | $114.19 | +57.63% | 2 | Apr 23, 2020 | |
| MYGN Myriad Genetics | Maintains: Underweight | $14 → $10 | $4.75 | +110.53% | 8 | Mar 26, 2020 | |
| IQV IQVIA Holdings | Maintains: Overweight | $192 → $166 | $173.26 | -4.19% | 4 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $51 → $43 | $75.65 | -43.16% | 9 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $170 → $154 | $173.89 | -11.44% | 7 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $435 → $430 | $279.99 | +53.58% | 6 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $435 → $430 | $278.25 | +54.54% | 6 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | n/a | $17.25 | - | 10 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $52 → $48 | $36.76 | +30.58% | 4 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $720 → $680 | $1,259.94 | -46.03% | 4 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $28 → $30 | $65.95 | -54.51% | 3 | Oct 2, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $295 → $300 | $491.46 | -38.96% | 5 | Mar 18, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $40 | $0.76 | +5,163.16% | 1 | Dec 11, 2017 |
Labcorp Holdings
Oct 2, 2025
Maintains: Equal-Weight
Price Target: $275 → $290
Current: $273.72
Upside: +5.95%
Agilent Technologies
Feb 28, 2024
Maintains: Underweight
Price Target: $120 → $125
Current: $115.48
Upside: +8.24%
Waters
Aug 3, 2023
Maintains: Equal-Weight
Price Target: $275 → $288
Current: $304.24
Upside: -5.34%
Avantor
Mar 3, 2021
Initiates: Overweight
Price Target: $33
Current: $7.90
Upside: +317.72%
Illumina
Mar 3, 2021
Initiates: Underweight
Price Target: $325
Current: $127.38
Upside: +155.14%
InMode
Aug 17, 2020
Maintains: Overweight
Price Target: $18 → $19
Current: $13.79
Upside: +37.78%
Quest Diagnostics
Apr 23, 2020
Maintains: Equal-Weight
Price Target: $93 → $99
Current: $198.02
Upside: -50.01%
ICON Public Limited Company
Apr 23, 2020
Maintains: Overweight
Price Target: $170 → $180
Current: $114.19
Upside: +57.63%
Myriad Genetics
Mar 26, 2020
Maintains: Underweight
Price Target: $14 → $10
Current: $4.75
Upside: +110.53%
IQVIA Holdings
Mar 26, 2020
Maintains: Overweight
Price Target: $192 → $166
Current: $173.26
Upside: -4.19%
Mar 26, 2020
Maintains: Equal-Weight
Price Target: $51 → $43
Current: $75.65
Upside: -43.16%
Mar 26, 2020
Maintains: Equal-Weight
Price Target: $170 → $154
Current: $173.89
Upside: -11.44%
Mar 26, 2020
Maintains: Overweight
Price Target: $435 → $430
Current: $279.99
Upside: +53.58%
Mar 26, 2020
Maintains: Overweight
Price Target: $435 → $430
Current: $278.25
Upside: +54.54%
Mar 26, 2020
Downgrades: Equal-Weight
Price Target: n/a
Current: $17.25
Upside: -
Mar 26, 2020
Upgrades: Overweight
Price Target: $52 → $48
Current: $36.76
Upside: +30.58%
Mar 26, 2020
Upgrades: Equal-Weight
Price Target: $720 → $680
Current: $1,259.94
Upside: -46.03%
Oct 2, 2019
Maintains: Underweight
Price Target: $28 → $30
Current: $65.95
Upside: -54.51%
Mar 18, 2019
Maintains: Overweight
Price Target: $295 → $300
Current: $491.46
Upside: -38.96%
Dec 11, 2017
Initiates: Equal-Weight
Price Target: $40
Current: $0.76
Upside: +5,163.16%